The Current and Future Landscape of SERCA Gene Therapy for Heart Failure: A Clinical Perspective

被引：30

作者：

Hayward, Carl ^{[1
]}

Banner, Nicholas R. ^{[2
]}

Morley-Smith, Andrew ^{[1
]}

Lyon, Alexander R. ^{[1
]}

Harding, Sian E. ^{[3
]}

机构：

[1] Royal Brompton Hosp, Cardiovasc Biomed Res Unit, London SW3 6NP, England

[2] Royal Brompton & Harefield NHS Trust, Harefield Hosp, Harefield UB9 6JH, Middx, England

[3] Univ London Imperial Coll Sci Technol & Med, London SW3 6NP, England

来源：

HUMAN GENE THERAPY | 2015年 / 26卷 / 05期

关键词：

SARCOPLASMIC-RETICULUM CA2+-ATPASE; SMOOTH-MUSCLE-CELLS; CALCIUM UP-REGULATION; NEUTRALIZING ANTIBODIES; DILATED CARDIOMYOPATHY; CARDIAC-FUNCTION; VENTRICULAR-ARRHYTHMIAS; MYOCARDIAL-INFARCTION; FAILING HUMAN; RAT MYOCYTES;

D O I：

10.1089/hum.2015.018

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Gene therapy has been applied to cardiovascular disease for over 20 years but it is the application to heart failure that has generated recent interest in clinical trials. There is laboratory and early clinical evidence that delivery of sarcoplasmic reticulum calcium ATPase 2a (SERCA2a) gene therapy is beneficial for heart failure and this therapy could become the first positive inotrope with anti-arrhythmic properties. In this review we will discuss the rationale for SERCA2a gene therapy as a viable strategy in heart failure, review the published data, and discuss the ongoing clinical trials, before concluding with comments on the future challenges and potential for this therapy.

引用

页码：293 / 304

页数：12

共 50 条

[31] GRK2 as a novel gene therapy target in heart failure
Rengo, Giuseppe
Lymperopoulos, Anastasios
Leosco, Dario
Koch, Walter J.
JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2011, 50 (05) : 785 - 792
[32] Gene targeting in ischemic heart disease and failure: Translational and clinical studies
Eckhouse, Shaina R.
Jones, Jeffrey A.
Spinale, Francis G.
BIOCHEMICAL PHARMACOLOGY, 2013, 85 (01) : 1 - 11
[33] Current Status of Stem Cell Therapy in Heart Failure
Das, Anjan Kumar
INDIAN JOURNAL OF SURGERY, 2023, 85 (SUPPL 2) : 381 - 384
[34] Endothelin in chronic heart failure: Current position and future prospects
Love, MP
McMurray, JJV
CARDIOVASCULAR RESEARCH, 1996, 31 (05) : 665 - 674
[35] New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides
Zhai, Yuting
Luo, Yuanyuan
Wu, Pei
Li, Dongye
JOURNAL OF MEDICAL GENETICS, 2018, 55 (05) : 287 - 296
[36] Adeno-Associated Virus Gene Therapy: Translational Progress and Future Prospects in the Treatment of Heart Failure
Bass-Stringer, Sebastian
Bernardo, Bianca C.
May, Clive N.
Thomas, Colleen J.
Weeks, Kate L.
McMullen, Julie R.
HEART LUNG AND CIRCULATION, 2018, 27 (11) : 1285 - 1300
[37] Gene Therapy Targets in Heart Failure: The Path to Translation
Raake, P. W. J.
Tscheschner, H.
Reinkober, J.
Ritterhoff, J.
Katus, H. A.
Koch, W. J.
Most, P.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (04) : 542 - 553
[38] Gene and cytokine therapy for heart failure: molecular mechanisms in the improvement of cardiac function
Nagai, Toshio
Komuro, Issei
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2012, 303 (05): : H501 - H512
[39] Gene Therapy for the Heart Lessons Learned and Future Perspectives
Cannata, Antonio
Ali, Hashim
Sinagra, Gianfranco
Giacca, Mauro
CIRCULATION RESEARCH, 2020, 126 (10) : 1394 - 1414
[40] Gene therapy for the treatment of heart failure: promise postponed
Hulot, Jean-Sebastien
Ishikawa, Kiyotake
Hajjar, Roger J.
EUROPEAN HEART JOURNAL, 2016, 37 (21) : 1651 - 1658

← 1 2 3 4 5 →